Key Takeaways FDA cleared Tecentriq and Tecentriq Hybreza with Zepzelca for ES-SCLC maintenance treatment.The IMforte study showed the combo cut progression or death risk by 46% versus Tecentriq alone.NCCN Guidelines now list the Tecentriq and Zepzelca combo as a preferred ES-SCLC maintenance option.Roche (RHHBY) announced that the FDA approved the label expansion of immunotherapy drug Tecentriq (atezolizumab).The FDA approved Tecentriq and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) in combinat ...